Capillary Leak Syndrome During ELZONRIS Treatment: Significant Pre-Dose Weight Gain
Clinical Scenario
This protocol applies to patients currently receiving ELZONRIS who exhibit a specific weight-based warning sign on routine pre-dose monitoring, indicating capillary leak syndrome requiring active management.
Pre-dose body weight increased by ≥ 1.5 kg above the previous day’s pre-dose weight.
Trigger Condition
During ELZONRIS treatment, each day’s pre-dose weight is compared to the prior day’s pre-dose weight. A gain of 1.5 kg or more on this pre-dose-to-pre-dose basis is the threshold that defines this capillary leak event and triggers the management protocol.
Management Approach
The protocol centres on intravenous albumin replacement, with the intensity and additional fluid management strategy tailored to the patient’s haemodynamic status at the time. Management continues until the defined resolution criteria are met. The complete structured regimen — including specific thresholds, sequencing, and escalation criteria — is available in the full protocol.
Treatment Goals
- Body weight increase resolved — pre-dose weight no longer ≥ 1.5 kg greater than the previous day’s pre-dose weight.
- Serum albumin ≥ 3.5 g/dL.
References
A pre-dose body weight that is increased by ≥ 1.5 kg over the previous day’s pre-dose weight
Weight gain ≥ 1.5 kg from the previous day’s pre-dose weight
Administer 25 g intravenous albumin (every 12 hours or more frequently as practical), and manage fluid status as indicated clinically (e.g., generally with intravenous fluids and vasopressors if hypotensive and with diuretics if normotensive or hypertensive), until body weight increase has resolved (i.e. the increase is no longer ≥ 1.5 kg greater than the previous day’s pre-dose weight).
Administer 25 g intravenous albumin (every 12 hours, or more frequently as practical) until serum albumin is ≥ 3.5 g/dL.
View source ↗